Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Accepts Filing of New Estrogen-Free Oral Contraceptive

By Exeltis division of Insud Pharma | November 30, 2018

Pharmaceutical multinational Exeltis has received acceptance from the U.S. Food and Drug Administration (FDA) of the filing of Slinda (4 mg Drospirenone-only pill), a novel oral contraceptive developed by the company.

Slinda is an investigational estrogen-free oral contraceptive, with a 24/4 dose regimen that is believed to have a favorable safety and efficacy profile.

“Once available in the market, it could give an improved bleeding profile and greater flexibility, maintaining contraception efficacy for up to 24 hours in the event of a delayed or missed pill dosage,” said Yann Brun, managing director at Exeltis.

Drospirenone is a synthetic progestin with a pharmacological profile similar to natural-produced progesterone. As an estrogen-free contraceptive option, Slinda is expected to reduce the cardiovascular risks associated with combined hormonal contraceptives (CHCs) and to offer the advantages of drospirenone in terms of safety and tolerability, according to Exeltis.

The submission of Slinda is based on a development program involving more than 3,000 patients, generating over 20,000 cycles. The study showed that Drospirenone 4 mg-only pill has a clinical efficacy historically comparable to CHCs.

“No cases of thromboembolic events were reported in the entire clinical program,” said Enrico Colli, M.D., chief scientific officer, “The safety profile was demonstrated for all women, even higher-risk population segments, such as smokers, over-35s and obese patients.”

(Source: Exeltis via PR Newswire)

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE